Le Lézard
Classified in: Health, Covid-19 virus
Subject: CCA

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Business Update


ENGLEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended September 30, 2021 and provide a corporate business update on Wednesday, November 10, 2021, at 4:30 pm EDT/ 2:30 pm MT.

Conference Call & Webcast:
Wednesday, November 10, 2021, 4:30 pm EDT / 2:30 pm MT
Webcast Link: https://event.on24.com/wcc/r/3499388/60A0DA16A47D6B146B1AA111CA73357E   
Conference Call (listen only): Canada dial-in number (Toll Free): 1 833 950 0062
          Canada dial-in number (Local): 1 226 828 7575
          United States: 1 844 200 6205
          United States (Local): 1 646 904 5544
          All other locations: +1 929 526 1599
          Access code: 385971

In order to submit questions, participants must have internet connectivity, as questions will only be addressed via the webcast.  The conference call line will be in listen only mode.

The conference call and webcast can also be accessed from the Investor Relations section of the Company's website at www.ampiopharma.com and will be archived there shortly after the live event.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampiontm, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and may be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act (BPCIA).

Forward Looking Statements

Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter  into partnering arrangements,  clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact
Katie Kennedy
katiek@gregoryfca.com
610-731-1045

SOURCE Ampio Pharmaceuticals, Inc.


These press releases may also interest you

27 nov 2021
Today IMV, part of Science and Medicine Group, the leading market research and business intelligence provider to the medical imaging industry, announced the category winners of the 2021 IMV ServiceTraktm Awards in diagnostic imaging equipment at RSNA...

27 nov 2021
On November 25th, 2021, the Chacruna Institute for Psychedelic Plant Medicines released its Guide to RFRA and Best Practices for Psychedelic Plant Medicine Churches. This Guide is a comprehensive resource on the Religious Freedom Restoration Act...

27 nov 2021
Following the inspiring opening speech, "Future Perspective of Cancer Immunotherapy," delivered by Nobel Prize and Tang Prize laureate Prof. Tasuku Honjo at the 14th Asia Pacific Federation of Pharmacologist Conference (APFP) on November 26, the 2020...

27 nov 2021
Trails Carolina, the leader in wilderness therapy for pre-teens and teens, teamed up with the Arkansas Institute of Developmental Science and the Center for Research, Assessment, and Treatment Efficacy to assess the impacts on youth and their...

26 nov 2021
Public Health Agency of Canada The Government of Canada is working with partners to protect the health and safety of Canadians and Temporary Foreign Workers in Canada, and to reduce the spread of COVID-19 and its variants in Canada. Self-isolation is...

26 nov 2021
Public health authorities in South Africa have confirmed that a new COVID-19 variant of concern (B.1.1.529) has been detected in that country. Over the past 24 hours, this variant ? named Omicron by the World Health Organization ? has also been...



News published on 28 october 2021 at 09:15 and distributed by: